Key result
SORT and SORT v2 outperform POSSUM in predicting 30-day pancreatic surgery mortality with AUC 0.98.
Why the study?
Pancreatic cancer surgery carries significant mortality, necessitating accurate perioperative risk assessment, but the accuracy of SORT and SORT v2 required validation in this population.
Do SORT and SORT v2 accurately predict 30-day mortality in patients undergoing pancreatic cancer surgery?
Observational (n=212)
No
Do SORT and SORT v2 accurately predict 30-day mortality in patients undergoing pancreatic cancer surgery?
SORT and SORT v2 provide excellent discrimination for predicting 30-day mortality in patients undergoing pancreatic cancer surgery, supporting their use in shared decision-making.
SORT models show strong performance in pancreatic cancer surgery; leaves open prospective validation before informing decisions.
BACKGROUND: Pancreatic cancer surgery is related to significant mortality, thus necessitating the accurate assessment of perioperative risk to enhance treatment decision making. A Surgical Outcome Risk Tool (SORT) and SORT v2 have been developed to provide enhanced risk stratification. Our aim was to validate the accuracy of SORT and SORT v2 in pancreatic cancer surgery. METHOD: Two hundred and twelve patients were included and underwent pancreatic surgery for cancer. The surgeries were performed by a single surgical team in a single tertiary hospital (2016-2022). We assessed a total of four risk models: SORT, SORT v2, POSSUM (Physiology and Operative Severity Score for the enumeration of Mortality and Morbidity), and P-POSSUM (Portsmouth-POSSUM). The accuracy of the model was evaluated using an observed-to-expected (O:E) ratio and the area under the curve (AUC). RESULTS: The 30-day mortality rate was 3.3% (7 patients). Both SORT and SORT v2 demonstrated excellent discrimination traits (AUC: 0.98 and AUC: 0.98, respectively) and provided the best-performing calibration in the total analysis. However, both tools underestimated the 30-day mortality. Furthermore, both reported a high level of calibration and discrimination in the subgroup of patients undergoing pancreaticoduodenectomy, with previous ERCP, and CA19-9 ≥ 500 U/mL. CONCLUSIONS: SORT and SORT v2 are efficient risk-assessment tools that should be adopted in the perioperative pathway, shared decision-making (SDM) process, and counseling of patients with pancreatic cancer undergoing surgery.
No takes yet. Share an insight, caveat, or question.
Karamolegkou et al. (2023) conducted an observational in Pancreatic cancer (n=212). Surgical Outcome Risk Tool (SORT) and SORT v2 vs. POSSUM and P-POSSUM was evaluated on Discrimination for 30-day mortality (AUC) (AUC 0.98, 95% CI 0.95-1.00, p=<0.001). SORT and SORT v2 demonstrated excellent discrimination for predicting 30-day mortality in pancreatic cancer surgery (AUC 0.98 for both), outperforming POSSUM and P-POSSUM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: